Central Nervous System Biomarkers Market 2022 - Market Demand, Growth Opportunities, Future Trends, Key Players, and Forecast to 2028
Central Nervous System Biomarkers Market-Overview
The improved accessibility to resources that can aid in
understanding the disease mechanisms is estimated to spur the central nervous
system biomarkers market. The market's report is efficiently analyzed as per
MRFR, which provides outlooks for the global markets. The market is predicted
to be motivated by a 13.0% CAGR leading to revenues worth USD 7,500 million by
2027.
The augmented use in diagnosing neurodegenerative diseases
is foreseen to transform the central nervous system biomarkers market in the
forecast period. The improved facilities available for research are estimated
to accelerate further the overall development of the Central
Nervous System Biomarkers Market, share in the course of the
forecast period.
Segmental Analysis
The segmental overview of the central nervous system
biomarkers market is carried out on the basis of type, application, end user,
and region.
·
The central nervous system biomarkers market
type segment consists of safety biomarkers, efficacy biomarkers, and validation
biomarkers.
·
The application segment of the central
nervous system biomarkers market consists of drug discovery &
development and personalized medicine.
·
The end user segment of the central nervous
system biomarkers market consists of diagnostic labs, hospitals &
clinics, and research centers.
·
The region segment of the central nervous
system biomarkers market consists of North America, Europe, Asia-Pacific,
and other important regional markets.
The chief players in the central nervous system biomarkers
market are
·
Merck & Co. (US, Abiant, Inc. (US),
·
Avacta Group plc (UK),
·
Diagenic Asa (Norway),
·
Thermo Fisher Scientific (US),
·
AbaStarMDx Inc. (US),
·
Banyan Biomarkers (US),
·
Avid Radiopharmaceuticals Inc. (US),
·
Acumen Pharmaceuticals Inc. (US),
·
Siemens AG (Germany)
·
Novartis (Switzerland).
Regional Overview
The regional evaluation of the central nervous system
biomarkers market consists of North America, Europe, Asia-Pacific, and other
important regional markets. Growing CNS cancer cases and R&D spending are
expected to boost central nervous system biomarkers market growth in this
region over the forecast period. Furthermore, businesses and research
institutes are continually inventing and developing new technologies and
biomarkers, which is aided by the presence of major competitors in the region
and increased R&D spending. The central nervous system biomarkers market in
Europe is being driven by an increase in demand for personalized/precision
medicine and the increased prevalence of neurological illnesses in the region.
Due to factors such as a huge customer base, high prevalence of CNS illnesses,
and improving healthcare infrastructure, the Asia-Pacific region is expected to
be the fastest-growing regional market throughout the forecast period.
Competitive Analysis
During the predicted period, the focus on accelerated growth
is expected to take center stage. The requirement to effectively engage clients
in all the geographical areas is expected to aid the market in overcoming the
current challenges. Furthermore, the market stakeholders need to ensure that long-term
sustainable growth targets are not endangered due to current difficulties. The
necessity to develop a competitive advantage over its competitors has a
significant impact on the global market. With a combination of innovation and
continuous product refinement, the market is expected to lead its future
expansion. The current market trends are making a significant contribution to
the industry's growth. The market contenders are expected to promote growth
enabling elements and, as a result, to bring the market out of the current
worldwide pandemic. The use of technology and a strategy-based approach is
likely to increase the likelihood of future success. The market's heightened
focus on high-revenue decision-making is expected to hasten its return to normalcy
in the coming months.
Industry Updates:
·
Feb 2021 The University of California, Berkeley
(UC Berkeley) and University of California, San Francisco (UCSF) have announced
a long-term research collaboration with Genentech, a member of the Roche Group,
and its parent firm, Roche Holding AG, to accelerate the development of new
therapeutics for debilitating brain diseases and central nervous system
disorders such as Parkinson's, Huntington's, Alzheimer's, ALS, and autism. UCSF
and UC Berkeley will accept up to $53 million from Genentech throughout the
10-year partnership.
·
Feb 2021 Woolsey Pharmaceuticals, a
clinical-stage company developing treatments for neurodegenerative diseases,
announced that the first patient in its FOUND (Fasudil fOr Uncontrolled
waNDering) study for Alzheimer's and Vascular Dementia patients with elopement
and getting lost had been dosed with BRAVYL. The first patient in the ROCKIT-1
(ROCK Inhibitor in Tauopathies – 1) trial of BRAVYL in patients with
Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS) has
started treatment, according to the company.
Related Report-
·
Global
Facial Rejuvenation Market Research Report—Forecast till 2027
·
Global
Whole Exome Sequencing Market Research Report—Forecast till 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment